Study guide

Generic Drug Stems, Labs, and Supportive Care Patterns

OCN Oncology Certified Nurse Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: OCN Exam Orientation and Official Source Control

Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness

2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care

Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures

3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment

Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation

4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards

Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development

5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy

Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation

6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents

Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation

7 Chapter 7: Symptom Management and Supportive Care

Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination

8 Chapter 8: Oncologic Emergencies and Rapid Escalation

Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

9 Chapter 9: Psychosocial Dimensions of Oncology Care

Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals

10 Chapter 10: Mixed OCN Case Labs

New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab

11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness

Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning

Generic Drug Stems, Labs, and Supportive Care Patterns

Key Takeaways Explain This Topic AI

ONCC uses generic drug names only, so final review should emphasize generic names, suffix stems, mechanisms, and signature toxicity clusters.

Drug stems aid recognition but do not replace knowing route, indication, monitoring, and patient-specific risk; some agents break the suffix rule.

Lab review should focus on values that change nursing assessment, escalation, education, and treatment readiness — for example ANC under 500, platelets under 50,000, or rising creatinine.

Supportive care items test prevention and early reporting of infection, bleeding, mucositis, neuropathy, nausea, diarrhea, constipation, and pain.

Anthracycline lifetime cumulative dose (doxorubicin around 450-550 mg/m2) and taxane/platinum hypersensitivity are recurring high-yield safety facts.

Last updated: June 2026

  • Generic Drug Stems, Labs, and Supportive Care Patterns
  • Review generic names only

ONCC tests use generic drug names only . In final review, pull brand-only flashcards and rewrite them as generics. A brand name may help you recognize a drug at the bedside, but no exam stem depends on it. Build last-week pharmacology around five anchors per agent: class, mechanism clue, common route, signature toxicities, and the one urgent teaching point.

Do not try to learn dosing for every regimen. The exam rewards recognizing the class, the danger signal, and the nursing response — not reciting milligrams. The exceptions worth memorizing are a handful of safety thresholds, covered below.

High-yield generic name stems

  • Stem Class Nursing review focus
  • mab Monoclonal antibody Infusion reactions, immune-related adverse events, target-specific toxicity
  • nib Kinase inhibitor (oral) Adherence, drug interactions, rash, diarrhea, hypertension, liver tests
  • parib PARP inhibitor Cytopenias, fatigue, nausea, reproductive precautions

-zomib Proteasome inhibitor Peripheral neuropathy, thrombocytopenia, herpes reactivation (antiviral prophylaxis)

  • ciclib CDK4/6 inhibitor Neutropenia, fatigue, diarrhea, agent-specific liver/QT monitoring
  • platin Platinum chemotherapy Nausea, nephrotoxicity, ototoxicity, peripheral neuropathy, hypersensitivity
  • taxel Taxane Hypersensitivity (premedicate), neuropathy, myelosuppression, alopecia
  • rubicin Anthracycline Cardiotoxicity, vesicant, myelosuppression, lifetime cumulative dose limit

Stems are clues, not guarantees — bortezomib (-zomib) and carfilzomib differ in cardiac risk, and not every -nib behaves identically. If a stem names a drug you only half-recognize, use the suffix to narrow the class, then return to the patient problem in the question.

Lab patterns and thresholds worth drilling

Lab / pattern Action threshold or meaning Why it matters for OCN

Absolute neutrophil count (ANC) Under 500 = severe neutropenia; under 1,000 and falling = high risk Neutropenic precautions; fever is a sepsis emergency

Platelets Under 50,000 = bleeding/procedure risk; under 10,000-20,000 = spontaneous bleed risk Bleeding precautions, fall risk, transfusion readiness

Hemoglobin Symptoms and trend drive action more than a single number Fatigue, dyspnea, activity tolerance, transfusion assessment

Creatinine (rising) Any acute rise on nephrotoxic therapy Hydration, dose-readiness, TLS or AKI concern

Liver transaminases (rising) 3-5x upper limit signals hepatotoxicity / immune hepatitis Treatment readiness, hold/escalate per orders

  • Potassium (high) Above ~5.0-5.5 with EKG change TLS or AKI; cardiac monitoring
  • Calcium LOW + phosphate HIGH Classic TLS chemistry Telemetry, hydration, urgent escalation
  • Calcium HIGH Above ~10.5 mg/dL corrected Hypercalcemia of malignancy; hydration, fall risk

Do not memorize labs as isolated numbers. The exam asks what the nurse should assess, teach, report, or prioritize . Always pair an abnormal value with symptoms and context: a potassium rise after high-burden leukemia therapy is an emergency; a stable chronic value already managed by the team is not.

Supportive care pattern table

Problem Assessment focus Teaching focus

Nausea/vomiting Intake, hydration, timing relative to therapy, antiemetic use Take antiemetics as scheduled; call for uncontrolled symptoms

Diarrhea Stools over baseline, blood, fever, dizziness Hydrate; report severe/persistent diarrhea; no self-treatment on immunotherapy

Constipation Opioids, intake, bowel pattern, obstruction signs Bowel regimen as prescribed; call for severe pain or vomiting

Mucositis Oral intake, pain, infection, bleeding Bland oral care; avoid alcohol/spicy/acidic foods; report inability to drink or fever

Peripheral neuropathy Falls, fine-motor change, pain, gait Safety measures; report worsening before injury

Fatigue Reversible causes (anemia, sleep, distress) Energy conservation, balanced activity, report severe change

Pain Location, quality, severity, function, side effects Scheduled plus breakthrough use; prevent constipation; safe storage

Final-week drug review method and traps

Write one line per agent: generic name, class stem, signature toxicity, urgent teaching point. Examples: paclitaxel — taxane — hypersensitivity and neuropathy — report dyspnea or chest tightness during infusion ; doxorubicin — anthracycline — cardiotoxicity and vesicant — track lifetime cumulative dose (around 450-550 mg/m2) and report IV-site burning ; pembrolizumab — checkpoint inhibitor — immune organ inflammation — report new diarrhea, cough, severe fatigue, rash, or jaundice early.

Common traps to refuse: telling a patient to wait out a neutropenic fever; normalizing new dyspnea on immunotherapy; instructing a patient to permanently stop oral therapy without contacting the team; recommending herbal supplements in place of evidence-based symptom care; or letting a familiar drug name distract you from the new safety problem in the stem.

Oral therapy adherence and growth factors

Oral anticancer agents now dominate targeted therapy, and the OCN reflects that shift with adherence and self-management items. Because the patient doses at home, teaching becomes the safety net: take the drug at the same time daily, do not double a missed dose without instruction, store away from children and heat, use gloves or avoid bare-hand splitting, and call the clinic for the specific toxicity thresholds (for example, several loose stools above baseline on a kinase inhibitor, or a new rash covering a large body area).

A patient who quietly skips doses to control diarrhea is a classic distractor scenario — the keyed answer assesses the reason and contacts the team, never simply praises the patient for stopping.

Supportive pharmacology rounds out the picture. Know that colony-stimulating factors (filgrastim, pegfilgrastim) support neutrophil recovery and reduce febrile-neutropenia risk but do not treat an active infection. Erythropoiesis-stimulating agents carry thrombosis and tumor-progression warnings, so they are used cautiously and not as a quick fatigue fix. Bone-modifying agents (zoledronic acid, denosumab) require dental evaluation because of osteonecrosis of the jaw risk and monitoring for hypocalcemia. Pairing each support drug with its single most-tested caution keeps these items fast and reliable.